Program
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868
Also written as “TQB2868 Injection” and “TQB2868 injection”.
In Sino Biopharmaceutical’s pipeline, 抗PD-1/TGF-β双功能融合蛋白
. Its studies are mostly in Pancreatic Neoplasms · Uterine Cervical Neoplasms, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 42 open or running | phase 3since Sep 3, 2025 | Jan 19, 2022 | Nov 2026phase 2 · NCT06767813 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB2868
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 19, 2022First study: phase 1 study in Advanced Malignant TumorFirst studyNCT05198505 · 280 enrolled · China
- Aug 8, 2023Phase 2 study in Uterine Cervical NeoplasmsNCT05998941 · China
- Jan 6, 2025Phase 2 study in Pancreatic NeoplasmsNCT06767813 · 80 planned · China
- Sep 3, 2025Phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07165951 · 566 planned · China
Ahead
- Nov 2026Primary completion: phase 2 study in Pancreatic NeoplasmsNCT06767813
- May 2028Primary completion: phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07165951
TargetBeta
“抗PD-1/TGF-β双功能融合蛋白”the company's pipeline, read by Claude · source
“A bifunctional fusion protein directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and transforming growth factor beta (TGF-beta; TGFb), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890rule | Incyte | phase 3 | 3 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma · China | 3 | Recruiting | May 2028 | 566 |
| NCT06767813Pancreatic Neoplasms · China | 2 | Recruiting | Nov 2026 | 80 |
| NCT05998941Uterine Cervical Neoplasms · China | 2 | Withdrawn | Feb 2025 | 0 |
| NCT05198505Advanced Malignant Tumor · China | 1 | UNKNOWN | Jun 2023 | 280 |
How it is read
Names in the registry
- “TQB2868 Injection”, 2 entries
- “TQB2868 injection”, 2 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Uterine Cervical Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.